Cell Therapy and Regenerative Medicine Company to Present at the 16th Annual B. Riley Investor Conference

0

Orgenesis Inc., today announced that their CEO, Ms. Vered Caplan will present Tuesday, May 12th at 10:00 a.m. Pacific Time at this year’s B. Riley & Co. Investor Conference. The 16th installment of this conference will be held at the Loews Hollywood Hotel in Los Angeles, California from May 12-14, 2015. Ms. Caplan will be available for one-on-one meetings during the event.

The cell therapy and regenerative medicine company uses a novel therapeutic technology dedicated to converting a patient’s own cells into functioning insulin producing cells as a treatment for diabetes. Orgenesis is a pioneer in terms of cellular transdifferentiation technology development. Basically, the process is reprogramming one cell type to function as another, different cell type. Orgenesis’ CEO will present on the Company’s technology, which represents a potential cure for Type 1 Diabetes by reprogramming human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).

About B. Riley & Co.

  1. Riley & Co., LLC is a leading investment bank which provides corporate finance, research, and sales & trading to corporate, institutional and high net worth individual clients. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, and merger and acquisitions advisory services. The firm is nationally recognized for its highly ranked proprietary equity research. B. Riley & Co., LLC is a member of FINRA and SIPC. For more information, please visit www.brileyco.com.

About Orgenesis Inc.

Orgenesis is a pre-clinical cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 Diabetes. In pursuit of this goal, the company has developed and patented a novel technology called “cellular trans-differentiation” that turns an insulin-dependent patient’s own liver cells into functional insulin producing cells. Orgenesis has proven that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult liver cells can be transformed into fully functional, beta cell-like insulin producing cells (IPCs). After ex-vivo expansion, the IPCs are re-infused via the portal vein of the diabetic patient. In pre-clinical models of Type 1 Diabetes (Non-Obese Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond to glucose challenge and successfully maintain glycemic homeostasis. In the same NOD model, the implanted IPCs were not subject to auto-immune attack or cellular ablation. Orgenesis plans to initiate P1/2 trials in the next 12-18 months. Orgenesis believes that converting the diabetic patient’s own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. For more information, visitwww.orgenesis.com.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; and that we will initiate Phase I and Phase II clinical trials in the near-term. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including, among others, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing; the ability to pass clinical trials so as to move on to the next phase; our ability to retain key employees; our ability to finance development and operations; our ability to satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Share.

About Author

Leave A Reply